Presentation is loading. Please wait.

Presentation is loading. Please wait.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Published byArmas Seppälä Modified over 6 years ago

Similar presentations

Presentation on theme: "Nat. Rev. Clin. Oncol. doi: /nrclinonc"— Presentation transcript:

1 Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2016.58
Figure 2 The most common adverse events in patients treated with ipilimumab, pembrolizumab, nivolumab, or ipilimumab plus nivolumab Figure 2 | The most common adverse events in patients treated with ipilimumab, pembrolizumab, nivolumab, or ipilimumab plus nivolumab. Incidence per 1,000 person-months. These incidences include data from the following studies: CA (Ref. 16), KEYNOTE-001 (Ref. 30), KEYNOTE-001 (randomized cohorts31), KEYNOTE-002 (Ref. 32), KEYNOTE-006 (Ref. 33), CheckMate-037 (Ref. 100), CheckMate-066 (Ref. 29), CheckMate-067 (Ref. 45), and CheckMate-069 (Ref. 44). Boutros, C. et al. (2016) Safety profiles of anti-CTLA‑4 and anti‑PD‑1 antibodies alone and in combination Nat. Rev. Clin. Oncol. doi: /nrclinonc

Download ppt "Nat. Rev. Clin. Oncol. doi: /nrclinonc"

Similar presentations

KEYNOTE-021: Pembrolizumab + Ipilimumab Active in Previously Treated Advanced NSCLC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*

KEYNOTE-021: Pembrolizumab + Ipilimumab Active in Previously Treated Advanced NSCLC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*
Brian Boulmay, MD LSUHSC- New Orleans Section of Hematology & Oncology

Brian Boulmay, MD LSUHSC- New Orleans Section of Hematology & Oncology
Bladder Cancer: A New Era in Treatment

Bladder Cancer: A New Era in Treatment
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.
Figure 2 Response after initial increase in total tumour burden

Figure 2 Response after initial increase in total tumour burden
Figure 3 Response after appearance of a new lesion

Figure 3 Response after appearance of a new lesion
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
State of the Art in HCC: Immune Checkpoint Modulation

State of the Art in HCC: Immune Checkpoint Modulation
Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.

Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.
Figure 2 Multiscale modelling in oncology

Figure 2 Multiscale modelling in oncology
Figure 5 Schematic illustration of different clinical trial designs

Figure 5 Schematic illustration of different clinical trial designs
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Optimizing the Treatment of Recurrent/Metastatic SCCHN

Optimizing the Treatment of Recurrent/Metastatic SCCHN
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio
Figure 3 Monitoring clonal evolution using liquid biopsies

Figure 3 Monitoring clonal evolution using liquid biopsies
Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.
Figure 2 Three-step approach to the assessment and management

Figure 2 Three-step approach to the assessment and management

Similar presentations

Ads by Google